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NLR family pyrin domain containing 3
(NLRP3) inflammasome gene
polymorphism rs7512998 (C>T) predicts
aging-related increase of blood pressure,
the TAMRISK study
Tarja Kunnas, Kirsi Määttä and Seppo T. Nikkari*
Abstract
Background: The activation of NLR family pyrin domain containing 3 (NLRP3) inflammasome by cellular stress leads
to activation of the inflammasome, and NLRP3 gene polymorphisms have been associated with autoinflammatory
diseases. Inflammasomes have also been implicated in the initiation or progression of metabolic disorders such as
atherosclerosis, type 2 diabetes and obesity. The association of NLRP3 genetic variant rs7512998 with blood
pressure and hypertension was studied in a 50-year-old Finnish cohort with a subpopulation who had available
data on blood pressure measurements also at the age of 45 years.
Results: NLRP3 gene polymorphism rs7512998 C-allele was associated with higher systolic (p = 0.006) and diastolic
(p = 0.011) blood pressure compared to the TT-genotype carriers in 50-year-old subjects. In addition, by analysis of
variance for repeated measures between ages of 45- and 50 years there was a significant time by genotype
interaction; blood pressure increased more in subjects with the C-allele both in systolic (p = 0.035) and diastolic
(p = 0.012) values. However, no association with diagnosed hypertension was found.
Conclusion: We report for the first time that NLRP3 gene polymorphism rs7512998 was associated with systolic and
diastolic blood pressure in 50-year-old subjects. In addition, an effect of this variation upon blood pressure was seen in
these same subjects in a 5-year follow-up from a 45-year-old cohort to 50 years of age.
Keywords: NLRP3, Human, Hypertension, Single nucleotide polymorphism, Health surveys
Background
There is increasing evidence that inflammasomes are
involved in the initiation or progression of diseases
including metabolic disorders such as atherosclerosis,
type 2 diabetes and obesity [1]. Inflammasomes are
large multimeric protein complexes and most of them
are formed with one or two family members of the
nucleotide-binding, leucine-rich repeat containing
proteins (NLR). Of the NLR family, pyrin domain
containing (NLRP) subfamily member NLRP3 is the
most studied and appears as the major sensor for
intracellular danger signals [2–5]. The activation of
NLRP3 by cellular stress leads to inflammasome acti-
vation catalyzing the formation of active proinflamma-
tory cytokines, interleukin (IL)-1β and IL-18, which
are then secreted [6–8]. Previous studies have sug-
gested an association of NLRP3 gene polymorphisms
and autoinflammatory diseases, such as type 1 dia-
betes and inflammatory bowel disease [4, 5]. Genetic
variability within NLRP3 may be also important in
the pathophysiology of abdominal aortic aneurysms
[9]. Multiple mutations in the NLRP3 gene are associ-
ated with markedly elevated serum IL-1β levels [10, 11].
A pivotal role of the inflammasome has been suggested
also in gout, where monosodium urate crystals activate
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NLRP3 [12]. In fact, genetic frequency of NLRP3 intronic
variant rs7512998 was significantly different between gout
and control patients [13]. There have been suggestions
that hypertension could have also an inflammatory back-
ground [14]. The SNP rs4986790 of the toll-like receptor
(TLR) four, which plays a key role in the innate immune
response and also participates in NLRP3 priming, has re-
cently been shown to associate with age-dependent blood
pressure increase in patients with coronary artery disease
[15]. However, no previous studies have investigated the
association of NLRP3 gene polymorphisms with elevated
blood pressure. Therefore, we wanted to assess the role of
NLRP3 gene rs7512998 variants in a Finnish 50-year-old
population, by analyzing cohorts from the Tampere adult
population cardiovascular risk study (TAMRISK) [16].
Results
Clinical characteristics of the cases (325) and controls
(444) at the age of 50 years are presented in Table 1.
The case group of hypertensive subjects was compared
to healthy controls. Cases had higher body mass index
(BMI), fasting glucose, and systolic and diastolic blood
pressure compared to controls. In the whole study popu-
lation the frequencies of the NLRP3 gene rs7512998 ge-
notypes were 0.02 for CC (n = 16), 0.28 for TC (n = 216)
and 0.70 (n = 537) for TT. These frequencies were in
Hardy-Weinberg equilibrium (p = 0.287), and did not
differ between cases and controls.
The statistical analysis of clinical characteristics be-
tween different genotype groups for NLRP3 gene are
given in Table 2. Subjects with C allele had significantly
higher systolic (p = 0.006) and diastolic (p = 0.011) blood
pressure at the age of 50 years than those homozygous
for the T allele. The difference between subjects with the
C allele and genotype TT was 3.4 mmHg in systolic
blood pressure and 1.9 mmHg in diastolic blood pres-
sure. This difference in blood pressure was not seen at
the age of 45 years. At the ages of 45 and 50 years there
were no differences between the genotype groups in
prevalence of hypertension, blood pressure medication,
BMI, serum cholesterol or glucose levels. Multivariate
analysis confirmed NLRP3 gene rs7512998 genotype as
an independent predictor of both systolic (Table 3) and
diastolic blood pressure (Table 4) at the age of 50 years.
In the same model, male gender and BMI were also such
predictors.
When the 45- and 50 year follow-up data of blood
pressure measurements in Table 2 was evaluated by ana-
lysis of variance for repeated measures, there was a sig-
nificant time by genotype interaction; blood pressure
increased more in subjects with the C-allele both in sys-
tolic (p = 0.035) and diastolic (p = 0.012) values.
Table 1 Clinical characteristics (means ± SD) of the study
population at the age of 50 years
Cases
(n = 325)
Controls
(n = 444)
P
Age (years) 50 ± 0 50 ± 0
Gender (male) % 59 63 0.279
Blood pressure medication (%) 73 0 <0.000
Smoking (%) 27 25 0.588
Body mass index (kg/m2) 28.8 ± 5.1 25.5 ± 3.6 <0.000
Cholesterol (mmol/l) 5.40 ± 0.98 5.37 ± 0.88 0.789
Glucose (mmol/l) 5.17 ± 1.30 4.86 ± 0.54 <0.000
Systolic blood pressure
(mm Hg)
142.7 ± 16.7 129.3 ± 14.8 <0.000
Diastolic blood pressure
(mm Hg)
92.8 ± 8.9 84.4 ± 9.1 <0.000
NLRP3 gene polymorphism
rs7512998 (CC/TC/TT) %
1.5/28.9/69.6 2.5/27.8/69.7 0.647
rs7512998 (CC+TC/TT) % 30.4/69.6 30.3/69.7 0.626
Table 2 Clinical characteristics (means ± SD) of the study
population stratified according to NLRP3 gene polymorphism
rs7512998. P values <0.05 are in bold
CC + TC TT p
N at 50 (%) 232 (30) 537 (70)
Hypertension (%) 41.2 42.3 0.807
Blood pressure medication (%) 28.1 32.2 0.273
Smoking (%) 23 28 0.128
Systolic blood pressure (mmHg) 137.6 (18.0) 134.0 (16.2) 0.006
Diastolic blood pressure (mmHg) 89.3 (10.2) 87.4 (9.6) 0.011
Body mass index (kg/m2) 27.3 (4.8) 26.8 (4.6) 0.196
Cholesterol (mmol/l) 5.4 (0.9) 5.4 (1.0) 0.959
Glucose (mmol/l) 5.0 (0.6) 5.1 (1.3) 0.309
N at 45 (%) 199 (29) 479 (71)
Hypertension (%) 12.6 16.2 0.253
Blood pressure medication (%) 7.6 12.4 0.083
Smoking (%) 42 42 0.911
Systolic blood pressure (mmHg) 133.3 (16.1) 132.4 (13.6) 0.417
Diastolic blood pressure (mmHg) 85.3 (9.5) 85.2 (9.2) 0.906
Body mass index (kg/m2) 26.7 (4.1) 26.3 (4.3) 0.219
Cholesterol (mmol/l) 5.5 (1.1) 5.5 (1.1) 0.617
Glucose (mmol/l) 5.4 (0.8) 5.2 (0.9) 0.449
Table 3 Linear regression for systolic blood pressure at the age
of 50 years
Parameter Coefficient B Std. error Beta P
Gender (Female = 0, Male = 1) 2.844 1.165 0.082 0.015
Body mass index 0.390 0.132 0.106 0.003
Hypertension (No = 0, Yes = 1) 12.376 1.228 0.359 <0.001
NLRP3 SNP 7512998
(TT = 0, CC+TC = 1)
3.361 1.236 0.091 0.007
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Discussion
We report that C-allele of the NLRP3 gene polymorph-
ism was significantly associated with higher blood pres-
sure compared to genotype TT at the age of 50 years. To
our knowledge, there are no previous studies showing
such an association. The C-allele of rs7512998 has previ-
ously been shown to be more common in gout patients
compared with controls, although 16 other NLRP3 gene
polymorphisms showed no such association [13]. In the
present study there was no association of C-allele with
blood pressure at the age of 45 years, but there was a
significant time by genotype interaction; blood pressure
increased more in subjects with the C-allele both in sys-
tolic and diastolic values by the age of 50 years. It is
known that a single gene variation on in GWAS studies
affects blood pressure +1.16 mmHg at the most [17]. At
the age of 50 years, the difference between subjects with
the C allele and genotype TT in systolic blood pressure
was +3.4 mmHg in systolic- and +1.9 mmHg in diastolic
blood pressure. The effect was not masked by blood
pressure medication, although practically all of the sub-
jects who had diagnosed hypertension were on medica-
tion at this age. It is to be noted that the NLRP3 gene
polymorphism was an independent predictor of both
systolic and diastolic blood pressure independently of
prior diagnosed hypertension, sex and BMI by multi-
variate analysis.
The observed increase in blood pressure in subjects
with the NLRP3 gene rs7512998 C-allele with aging may
be linked to modified activation of NLRP3 by aging-
related reactive oxygen species (ROS) production by
damaged mitochondria. This process of inflammasome
activation through NLRP3 is present in many age‐related
conditions, such as obesity, and type 2 diabetes [18]. An
anti-oxidant has been shown to ameliorate experimental
pulmonary artery hypertension via inhibiting NLRP3
inflammasome signal pathway in rats [19]. NLRP3
causes activation of inflammatory caspases which acti-
vate precursors of IL‐1β and IL‐18 and stimulate their
secretion. Among other cytokines, IL-1β and IL‐18 are
known to be an important modulators in artery wall in-
flammation and acceleration of atherosclerosis [20–22].
A cholesterol crystal-induced further NLRP3 inflamma-
some activation in macrophages may represent an
important link between cholesterol metabolism and in-
flammation in atherosclerotic lesions [23]. The NLRP3
gene polymorphism Q705K (rs35829419) has been
shown to confer a protective effect against the risk of de-
veloping MI in females [24].
The toll-like receptors (TLR) are transmembrane pro-
teins that are important for immune surveillance at the
cell surface and endolysosomal compartments, recogniz-
ing a wide range of microbial structures and endogenous
danger signals. In most cell types inflammasome activa-
tion commonly includes priming with a TLR agonist,
such as lipopolysaccharide (LPS), which induces elevated
expression of NLRP3 [25]. Once primed, NLRP3 may
respond to danger signals and form the NLRP3 inflam-
masome. Our present results and a recent similar
observation of an association with age-dependent blood
pressure increase with TLR4 SNP rs4986790 genotype
[15] may suggest that increase of inflammasome action
is related to increase in blood pressure.
There was a gender bias since in multivariate analysis
male gender was a predictor of both systolic and dia-
stolic blood pressure. However, multivariate analysis also
showed that C-allele of the NLRP3 rs7512998 gene poly-
morphism was significantly associated with higher blood
pressure, independently of gender and BMI. Life-style
factors such as smoking and exercise contribute to
inflammation, metabolic syndrome and blood pressure
increase. However, in regard to smoking and BMI, there
were no differences between genotype groups.
The study group was restricted to residents of a large
city in Finland, posing a challenge to how broadly one
can apply the findings. Since the study subjects are from
a restricted genetic pool (Finnish Caucasian), the find-
ings might not be extrapolated to different genetic
populations. Replication studies should be called for
to explore more fully the findings with further consider-
ation of the molecular mechanisms. In addition, each
registration of blood pressure was made at one examin-
ation visit only, and most of the subjects with hyperten-
sion were already on medication by the age of 50 years. It
is also clear that information on medication had not been
provided by some of the participants with hypertension,
since the percentage of these with recorded blood
pressure treatment was only 73 %.
Conclusions
In conclusion, our results indicate that NLRP3 gene
polymorphism rs7512998 is associated with systolic and
diastolic blood pressure in 50-year-old subjects in the
TAMRISK study. Between ages of 45- and 50 years
blood pressure increased more in subjects with the C-
allele. Age-related increase in blood pressure could have
an inflammatory background where NLRP3 inflamma-
some action may be involved.
Table 4 Linear regression for diastolic blood pressure at the
age of 50 years
Parameter Coefficient B Std. error Beta P
Gender (Female = 0, Male = 1) 3.206 0.655 0.158 <0.001
Body mass index 0.388 0.074 0.181 <0.001
Hypertension (No = 0, Yes = 1) 7.278 0.690 0.363 <0.001
NLRP3 SNP 7512998
(TT = 0, CC+TC = 1)
1.623 0.694 0.075 0.020
Kunnas et al. Immunity & Ageing  (2015) 12:19 Page 3 of 5
Methods
Subjects
TAMRISK study data was collected from periodic health
examinations (PHE) done for 50-year-old men and
women living in Tampere, a city in southern Finland
with 220 000 inhabitants [16]. Basic evaluation in 1988–
91 included an interview by a public health nurse. The
interview was conducted using a structured question-
naire about health and health-related behavior. Current
and previous diseases were identified based on self-
report of diagnosis by a physician, including hyperten-
sion. Registration of blood pressure (mm of mercury)
was made at the examination visit using a calibrated
mercury sphygmomanometer using the first Korotkoff
sounds for determination of systolic blood pressure and
the last Korotkoff sounds for diastolic blood pressure.
Subjects were seated in a chair with back support for at
least 5 min prior to obtaining a measurement. Height
(cm) and weight (kg) were recorded from which the
body mass index (BMI) was calculated. Serum total chol-
esterol (mmoles/l) and glucose (mmoles/l) were mea-
sured after an overnight fast by standard techniques.
Buccal swabs for DNA extraction and a permissions
form to use PHE data were collected by mail separately
of the physical examination. The DNA samples were
collected during years 2006–2010. Informed consent was
obtained from all participants. The Ethics Committees
of the Tampere University Hospital and the City of Tam-
pere approved the study.
Cases (n = 325) were subjects who had hypertension at
the age of 50 years (as diagnosed by a physician) and
for each case, at least one normotensive control subject
(n = 444) with the same sex and similar smoking
habits, was chosen in order of admission from a PHE
cohort (n = 6000). The present study population at
the age of 50 years thus included 769 subjects. Of
these same individuals, we also analyzed the subpopula-
tion of men and women who had available previous PHE
data from the age of 45 years (n = 678), Both 50- and
45 year PHEs were conducted in a similar fashion by the
same organization.
Baseline measurements
Genotyping
DNA was extracted from buccal swabs using a commer-
cial kit (Qiagen Inc., Valencia, Calif., USA). The samples
were transferred into 96-well plates and genotyped for
NLRP3 gene polymorphism rs7512998 at the KBioscience
Institute (UK) using Competitive Allele Specific PCR
(KASP) technique.
Statistical analysis
Sample size was calculated by Quanto 1.2.4 (Copyright©
2000–2009, University of Southern California), with a
choice of gene-only model. According to the World
Health Organization a prevalence ratio of raised
blood pressure in adults aged over 25 is about 40 %
(http://www.who.int/gho/ncd/risk_factors/blood_pressure_
prevalence_text/en/). The C-allele frequency of NLRP3
gene polymorphism rs7512998 was 0.1599 reported
by National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/snp/?term=rs7512998). Using
80 % power, a type I error rate of 0.05 and a two-sided
statistical test, the required sample size per group was
calculated to be 99. A total of 325 cases and 444 con-
trols with successful genotyping were included in the
final study population.
T-test for continuous variables and Chi-square test for
categorical variables were applied for the comparison of
groups. If the distribution was skewed, the analysis was
performed using transformed values to approximately
normalize the distribution. The analysis of variance for
repeated measures was used to assess the differences in
mean blood pressures between genotypes at the age of
45- and 50 years. Association analysis for NLRP3 gene
rs7512998 genotype as a predictor of systolic and dia-
stolic blood pressure was done using linear regression
with gender, BMI and diagnosis of hypertension as co-
factors. Analyses were carried out using SPSS 20.0 for
Windows (SPSS Inc., Chicago, Illinois, USA).
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